326P - Intercontinental Cooperative Non-Hodgkin T cell Lymphoma Prospective Registry Study (326P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Lymphomas
Cancer Aetiology, Epidemiology, Prevention
Haematologic Malignancies
Presenter Silvia Park
Citation Annals of Oncology (2017) 28 (suppl_10): x94-x99. 10.1093/annonc/mdx664
Authors S. Park, W.S. Kim, S.J. Kim
  • Department Of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR



T cell lymphomas are a relatively rare and heterogeneous group of disease. Because of its rarity and diversity, most published data have been based on small, and single-center retrospective studies.


Here, we conducted a multi-center, prospective registry study of non-Hodgkin T cell lymphoma. From April 2016 to Dec 2016, a total of 85 patients who were diagnosed as mature T cell non-Hodgkin lymphoma based on the World Health Organization Classification 2008 were enrolled (Korea, n = 59; China, n = 13; Taiwan, n = 8; Indonesia, n = 4; Singapore, n = 1). Among them, data from 49 patients were used in this interim analysis.


The median age was 56 years. Among the patients enrolled, extranodal NK T cell lymphoma was the most common disease accounting for 34.7% (n = 17), and AITL (24.5%, n = 12), PTCL (22.4%, n = 11), ALCL (10.2%, n = 5), EATL (4.1%, n = 2), Cutaneous T cell lymphoma (2.0%, n = 1), and T-LBL were followed (2.0%, n = 1). CHOP based regimen was most commonly used as 1st line treatment, which comprised 75% of all regimens used except in the case of extranodal NK T cell lymphoma. Except patients whose treatment response to 1st line therapy was unknown (n = 10) or not evaluable (n = 6), complete response, partial response, stable disease and progressive disease were reported in 17 (51.5%), 3 (9.1%), 3 (9.1%) and 10 patients (30.3%). Overall, 10 patients proceeded autologous transplantation (20.4%), and 7 of whom underwent transplantation as an upfront treatment. Median overall survival was not reached due to a short period of follow up (median 6.6 months).


This study shows interim results of clinical response and patient outcome of non-Hodgkin T cell lymphoma in real world treatment practice. The study is still ongoing, and further data collection is needed to provide information useful for establishing effective treatment strategies.

Clinical trial identification

NCT 02691351

Legal entity responsible for the study

CISL and centers from Asia countries and centers from Latin America and European countries may enroll patients in the study.




All authors have declared no conflicts of interest.